| Gene Symbol | MAPT |
| Full Name | Mutant Neurons |
| Aliases | H1/H2 |
| Chromosome | 17q21.31 |
| Protein Type | Structural Protein |
| Target Class | Structural Protein |
| Function | Tau aggregation inhibitors, anti-tau antibodies, tau phosphorylation modulators |
| Mechanism of Action | Tau aggregation inhibitors, anti-tau antibodies, tau phosphorylation modulators |
| Druggability | Medium (0.45) |
| Clinical Stage | Phase III |
| Molecular Weight | 65 kDa |
| Amino Acids | 441 aa |
| Exons | 16 |
| Pathways | Amyloid, Apoptosis, Autophagy, Camp Signaling, Cholesterol |
| UniProt ID | A0A7I2PJZ2 |
| GeneCards | MAPT |
| Human Protein Atlas | MAPT |
| Associated Diseases | AD, ALS, AMI, Ad Pathology, Aging |
| Known Drugs/Compounds | Flavonoids, 13G4, berberine |
| Interactions | PARP1, PEN2, PSEN1, DAPK1, HSPG2, IL1B |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Glymphatic-Mediated Tau Clearance Dysfunction Selective Tau Kinase Inhibition in Vulnerable Neur Dual-Circuit Tau Vulnerability Cascade (+8 more) |
| KG Connections | 1836 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |